In a research report published today to investors, Brean Capital analyst Jonathan Aschoff maintained a Buy rating on Merrimack Pharmaceuticals (NASDAQ:MACK) with a $16 …
In a research report issued today, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on Merrimack Pharmaceuticals (NASDAQ:MACK) with a $16 price …
In a research report released Wednesday, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on Merrimack Pharmaceuticals (NASDAQ:MACK) with a $16 price target, …
